1. Home
  2. JCI vs REGN Comparison

JCI vs REGN Comparison

Compare JCI & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Johnson Controls International plc

JCI

Johnson Controls International plc

HOLD

Current Price

$113.54

Market Cap

71.6B

Sector

Industrials

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$807.21

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JCI
REGN
Founded
1885
1988
Country
Ireland
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.6B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
JCI
REGN
Price
$113.54
$807.21
Analyst Decision
Buy
Buy
Analyst Count
15
23
Target Price
$122.71
$805.87
AVG Volume (30 Days)
5.6M
811.7K
Earning Date
02-04-2026
01-30-2026
Dividend Yield
1.40%
0.45%
EPS Growth
99.55
2.88
EPS
5.03
41.59
Revenue
$23,596,000,000.00
$14,247,800,000.00
Revenue This Year
$6.36
$1.99
Revenue Next Year
$5.54
$6.68
P/E Ratio
$22.65
$18.67
Revenue Growth
2.81
2.89
52 Week Low
$68.03
$476.49
52 Week High
$124.07
$792.77

Technical Indicators

Market Signals
Indicator
JCI
REGN
Relative Strength Index (RSI) 38.91 67.89
Support Level $108.41 $753.20
Resistance Level $124.07 $779.75
Average True Range (ATR) 2.37 15.38
MACD -0.72 -0.74
Stochastic Oscillator 31.70 96.07

Price Performance

Historical Comparison
JCI
REGN

About JCI Johnson Controls International plc

Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: